{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:56:33Z","timestamp":1775091393738,"version":"3.50.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s12325-023-02551-9","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T16:02:14Z","timestamp":1686931334000},"page":"3291-3303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"2551_CR1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1182\/hematology.2022000396","volume":"2022","author":"P Rodriguez-Otero","year":"2022","unstructured":"Rodriguez-Otero P, San-Miguel JF. Cellular therapy for multiple myeloma: what\u2019s now and what\u2019s next. Hematol Am Soc Hematol Educ Progr. 2022;2022:180\u20139.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"2551_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1182\/hematology.2022000334","volume":"2022","author":"C Cipkar","year":"2022","unstructured":"Cipkar C, Chen C, Trudel S. Antibodies and bispecifics for multiple myeloma: effective effector therapy. Hematol Am Soc Hematol Educ Progr. 2022;2022:163\u201372.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"2551_CR3","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1080\/10428194.2022.2113532","volume":"63","author":"D Kazandjian","year":"2022","unstructured":"Kazandjian D, Kowalski A, Landgren O. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape. Leuk Lymphoma. 2022;63:3032\u201343.","journal-title":"Leuk Lymphoma"},{"key":"2551_CR4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2022-159707","volume":"140","author":"A Chari","year":"2022","unstructured":"Chari A, Touzeau C, Schinke C, et al. Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): Phase\u00a01\/2 results from MonumenTAL-1. Blood. 2022;140:384\u20137.","journal-title":"Blood"},{"key":"2551_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1182\/blood-2022-166494","volume":"140","author":"N Raje","year":"2022","unstructured":"Raje N, Bahlis NJ, Costello C, et al. Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma. Blood. 2022;140:388\u201390.","journal-title":"Blood"},{"key":"2551_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1182\/blood-2022-162440","volume":"140","author":"NJ Bahlis","year":"2022","unstructured":"Bahlis NJ, Tomasson MH, Mohty M, et al. Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma na\u00efve to B-cell maturation antigen (BCMA)-directed therapies: results from cohort\u00a0A of the Magnetismm-3 study. Blood. 2022;140:391\u20133.","journal-title":"Blood"},{"key":"2551_CR7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1182\/blood-2022-159711","volume":"140","author":"E Searle","year":"2022","unstructured":"Searle E, Quach H, Wong SW, et al. Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a phase\u00a01b, multicohort study. Blood. 2022;140:394\u20136.","journal-title":"Blood"},{"key":"2551_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2022-157988","volume":"140","author":"C Carlo-Stella","year":"2022","unstructured":"Carlo-Stella C, Mazza R, Manier S, et al. RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (sc) results from a phase I dose-escalation study. Blood. 2022;140:397\u20139.","journal-title":"Blood"},{"key":"2551_CR9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1182\/blood-2022-159009","volume":"140","author":"SW Wong","year":"2022","unstructured":"Wong SW, Bar N, Paris L, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) \u00d7 CD3 T-cell engager (TCE), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from a phase\u00a01 first-in-human clinical study. Blood. 2022;140:400\u20132.","journal-title":"Blood"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02551-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02551-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02551-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T03:24:37Z","timestamp":1688959477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02551-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2551"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02551-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"assertion":[{"value":"1 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}